Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lentiviral FVIII Gene Therapy for Hemophilia A
NCT03217032Phase 1Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- May 2028
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YUVA-GT-F801 in hemophilia A, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Adverse Events at 1 year. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
YUVA-GT-F801
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03217032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217032.